《大行報告》里昂上調新東方(EDU.US)目標價至53.4美元 評級「買入」
里昂發表研究報告指,新東方(EDU.US)2023財年第二季的收入為6.38億美元(下同),勝於預期;淨利潤為100萬元,而去年同期的淨虧損為9.37億元。集團對2023財年第三季度的收入指引為7.03億至7.2億元,料2023財年收入為27至28億美元,非通用會計準則營運利潤率約為8%。新業務和新東方在線(01797.HK)是主要的驅動力。該行將集團目標價由51.5元上調至53.4元,重申「買入」評級。
該行表示,考慮到集團的業績、在管理層指引下對業務的更樂觀前景,以及股票回購速度較預期慢。隨著股價上漲,近農曆新年期間可能會出現一些獲利回吐,但亦為長期投資者提供了機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.